semaglutide average weight loss Results after 4 weeks on Semaglutide, also known as Ozempic,

Another GLP-1R/GIPR/GCGR triple agonists, Efocipegtrutide (HM15211, Hanmi Pharmaceutical, Seoul, South Korea), has completed phase 1 for treatment of obesity (NCT03374241) and is currently in phase 2 for treatment of MASH (NCT04505436)

This extends the GH-stimulating signal from minutes to days

Read the full article in Journal of Substance Abuse Treatment: Learn more about the implementation research in addiction: #ImplementationScience #AddictionResearch #EvidenceBased #NIH #NIDA #PublicHealth #ResearchToPractice To view or add a comment, sign in Seventeen Years of Progress in NIDAs Investment in Implementation Research: How Far Weve Come

India also faces a rapid rise in obesity, WHO found

That said, it can be tempting to want to rush increasing your dose if you feel you arent seeing results quickly enough